A Randomized, Double-Blind Trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate for the Treatment of Patients With Polyarticular Juvenile Rheumatoid Arthritis.
Latest Information Update: 13 Apr 2010
Price :
$35 *
At a glance
- Drugs Infliximab (Primary) ; Methotrexate (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Centocor
- 01 Apr 2010 Results from long-term extension study available in the Annals of the Rheumatic Diseases.
- 19 Jul 2008 New trial record.